AR110241A1 - Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos - Google Patents

Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos

Info

Publication number
AR110241A1
AR110241A1 ARP170103293A ARP170103293A AR110241A1 AR 110241 A1 AR110241 A1 AR 110241A1 AR P170103293 A ARP170103293 A AR P170103293A AR P170103293 A ARP170103293 A AR P170103293A AR 110241 A1 AR110241 A1 AR 110241A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
nrn
cycloalkyl
heterocyclyl
Prior art date
Application number
ARP170103293A
Other languages
English (en)
Inventor
Stefan Peters
Holger Wagner
Matthias Eckhardt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR110241A1 publication Critical patent/AR110241A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos que tienen valiosas propiedades farmacológicas que, en particular, se unen al receptor GPR40 y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que pueden ser influenciadas por este receptor, tales como las enfermedades metabólicas, en particular la diabetes de tipo 2. Además, productos intermedios, útiles para la síntesis de tales compuestos. Reivindicación 1: Un compuesto caracterizado por la fórmula (1), en la que R se selecciona del grupo que consiste en H, F, Cl, Br, I, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, NC-, HNRN-C(=O)-, alquilo C₁₋₄-NRN-C(=O)-, cicloalquilo C₃₋₆-NRN-C(=O)-, heterociclilo-NRN-C(=O)-, heteroarilo-NRN-C(=O)-, HOOC-, alquilo C₁₋₄-OC(=O)-, O₂N-, HRNN-, alquilo C₁₋₄-RNN-, alquilo C₁₋₄-C(=O)NRN-, cicloalquilo C₃₋₆-C(=O)NRN-, heterociclilo-C(=O)-NRN-, heteroarilo-C(=O)NRN-, alquilo C₁₋₄-S(=O)₂NRN-, cicloalquilo C₃₋₆-S(=O)₂NRN-, heterociclilo-S(=O)₂NRN-, heteroarilo-S(=O)₂NRN-, HO-, alquilo C₁₋₆-O-, HOOC-alquilo C₁₋₃-O-, heterociclilo C₁₋₃-O-, fenil-alquilo C₁₋₃-O-, cicloalquilo C₃₋₆-O-, heterociclilo-O-, heteroarilo-O-, alquilo C₁₋₄-S-, cicloalquilo C₃₋₆-S-, heterociclilo-S-, alquilo C₁₋₄-S(=O)-, cicloalquilo C₃₋₆-S(=O)-, heterociclilo-S(=O)-, alquilo C₁₋₄-S(=O)₂-, cicloalquilo C₃₋₆-S(=O)₂-, heterociclilo-S(=O)₂-, fenilo-S(=O)₂-, heteroarilo-S(=O)₂-, HNRN-S(=O)₂-, alquilo C₁₋₄-NRN-S(=O)₂-, heterociclilo, fenilo, y heteroarilo, en la que cada grupo o subgrupo alquilo, cicloalquilo, y heterociclilo dentro de los grupos que forman R está opcionalmente sustituido con 1 o más átomos de F y opcionalmente sustituido con 1 a 3 grupos seleccionados en forma independiente de Cl, alquilo C₁₋₃, NC-, (RN)₂N-, HO-, alquilo C₁₋₃-O-, y alquilo C₁₋₃-S(=O)₂-; y en el que cada grupo o subgrupo fenilo y heteroarilo dentro de los grupos que forman R está opcionalmente sustituido con 1 a 5 sustituyentes seleccionados en forma independiente de F, Cl, alquilo C₁₋₃, HF₂C-, F₃C-, NC-, (RN)₂N-, HO-, alquilo C₁₋₃-O-, F₃C-O-, y alquilo C₁₋₃-S(=O)₂-; en la que cada grupo o subgrupo heterociclilo dentro de los grupos que forman R se selecciona de un grupo ciclobutilo en el que 1 grupo CH₂ está reemplazado por NRN- u -O-; un grupo cicloalquilo C₅₋₆ en el que 1 grupo CH₂ está reemplazado por -C(=O)-, NRN-, -O- o -S(=O)₂- y/o 1 grupo CH está reemplazado por N; un grupo cicloalquilo C₅₋₆ en el que 1 grupo CH₂ está reemplazado por NRN- u -O-, un segundo grupo CH₂ está reemplazado por NRN-, -C(=O)- o -S(=O)₂- y/o 1 grupo CH está reemplazado por N; y un grupo cicloalquilo C₅₋₆ en el que 2 grupos CH₂ están reemplazados por NRN- o 1 grupo CH₂ por -NRN- y el otro por -O- y un tercer grupo CH₂ está reemplazado por -C(=O)- o -S(=O)₂- y/o 1 grupo CH está reemplazado por N; en el que cada grupo o subgrupo heteroarilo dentro de los grupos que forman R se selecciona de tetrazolilo y un anillo heteroaromático de 5 ó 6 miembros que contiene 1, 2, ó 3 heteroátomos en forma independiente el uno del otro seleccionados de =N-, -NRN-, -O-, y -S-, en el que en los grupos heteroaromáticos que contienen una unidad -HC=N- este grupo está reemplazado en forma opcional por -NRN-C(=O)-; en el que en los anillos de heteroarilo y heterociclilo con uno o más grupos NH, cada uno de dichos grupos NH está reemplazado por NRN; R¹ se selecciona del grupo que consiste en H, F, Cl, alquilo C₁₋₄, cicloalquilo C₃₋₆, HO-alquilo C₁₋₄, alquilo C₁₋₄-O-alquilo C₁₋₄, NC-, HO-, alquilo C₁₋₄-O-, cicloalquilo C₃₋₆-O-, alquilo C₁₋₄-S-, alquilo C₁₋₄-S(O)-, y alquilo C₁₋₄-S(O)₂-, en el que cualquier grupo o subgrupo alquilo y cicloalquilo dentro de los grupos que forman R¹ está opcionalmente sustituido con 1 o más átomos de F, y en el que múltiples R¹ pueden ser iguales o diferentes si mes es 2, 3 ó 4; m es un número entero seleccionado de 1, 2, 3, y 4; R² se selecciona del grupo que consiste en H, F, Cl, alquilo C₁₋₄, NC-, y alquiloxi C₁₋₄, en el que cualquier grupo o subgrupo alquilo dentro de los grupos que forman R² está opcionalmente sustituido con 1 o más átomos de F, y en el que múltiples R² pueden ser idénticos o diferentes si n es 2 ó 3; R³ se selecciona del grupo que consiste en H, F, Cl, alquilo C₁₋₄, NC-, y alquilo C₁₋₄-O-, en el que cada grupo o subgrupo alquilo dentro de los grupos que forman R³ está opcionalmente sustituido con 1 o más átomos de F; n es un número entero seleccionado de 1, 2, y 3; RN está seleccionado independientemente uno de otro del grupo que consiste en H, alquilo C₁₋₄, HO-alquilo C₁₋₄-(H₂C)-, alquilo C₁₋₃-O-alquilo C₁₋₄, alquilo C₁₋₄-C(=O)-, alquilo C₁₋₄-NH-C(=O)-, alquilo C₁₋₄-N(alquilo C₁₋₄)-C(=O)-, alquilo C₁₋₄-OC(=O)-, y alquilo C₁₋₄-S(=O)₂-, en el que cada grupo o subgrupo alquilo dentro de los grupos que forman RN está opcionalmente sustituido con 1 o más átomos de F; en la que en cualquier definición mencionada con anterioridad, si no se específica otra cosa, cualquier grupo o subgrupo alquilo pueden ser de cadena lineal o ramificada; o una sal del mismo. Reivindicación 17: Un compuesto caracterizado por la estructura y la estereoquímica que se muestra en las fórmulas (2), (3), (4) y (5), en las que R³ es H, R’ es H o alquilo C₁₋₄, y LG es Cl, Br, o I; o una sal de los mismos.
ARP170103293A 2016-11-28 2017-11-27 Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos AR110241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16200889 2016-11-28

Publications (1)

Publication Number Publication Date
AR110241A1 true AR110241A1 (es) 2019-03-13

Family

ID=57406160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103293A AR110241A1 (es) 2016-11-28 2017-11-27 Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos

Country Status (7)

Country Link
US (1) US10125101B2 (es)
EP (1) EP3544958B1 (es)
JP (1) JP7008704B2 (es)
CN (1) CN110312706B (es)
AR (1) AR110241A1 (es)
TW (1) TW201831451A (es)
WO (1) WO2018095877A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US628476A (en) 1898-03-18 1899-07-11 Joseph Howard Kirk Junction of cycle, motor-car, or other frames, &c.
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
PE20061127A1 (es) 2005-02-15 2006-10-21 Glaxo Group Ltd Derivados de propanosulfonamida que potencian el receptor de glutamato
JP2008534567A (ja) 2005-03-28 2008-08-28 ファイザー株式会社 Ｖｒ１受容体アンタゴニストとしての置換アリールオキソエチルシクロプロパンカルボキサミド化合物
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP2009530237A (ja) 2006-03-15 2009-08-27 ノイロサーチ アクティーゼルスカブ キナゾリノン及びカリウムチャネル活性化剤としてのその使用
CA2727340A1 (en) 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
WO2010051819A1 (en) 2008-11-10 2010-05-14 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
EP2748151B1 (en) * 2011-08-25 2016-03-16 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8633182B2 (en) * 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
JP6533778B2 (ja) 2013-09-26 2019-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ４０アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体
EP3074375B1 (en) 2013-11-28 2018-04-04 Boehringer Ingelheim International GmbH New indanyloxyphenylcyclopropanecarboxylic acids
WO2017025368A1 (en) * 2015-08-07 2017-02-16 Boehringer Ingelheim International Gmbh Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
EP3347358B1 (en) * 2015-09-09 2019-11-27 Boehringer Ingelheim International GmbH [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
US20180148411A1 (en) 2018-05-31
JP2019535792A (ja) 2019-12-12
CN110312706A (zh) 2019-10-08
JP7008704B2 (ja) 2022-01-25
TW201831451A (zh) 2018-09-01
CN110312706B (zh) 2023-08-18
EP3544958A1 (en) 2019-10-02
EP3544958B1 (en) 2021-03-24
WO2018095877A1 (en) 2018-05-31
US10125101B2 (en) 2018-11-13

Similar Documents

Publication Publication Date Title
AR110241A1 (es) Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR090493A1 (es) Acidos indaniloxidihidrobenzofuranilaceticos
CL2017002609A1 (es) Compuestos derivados de pirazolopiridina hidrogenadas, inhibidores p2x7, composición farmacéutica que los comprende; proceso de preparación de estos; y su uso en el tratamiento de enfermedades oseas, sns, cardiovasculares, entre otras (divisional de cl 2655-2015)
AR102948A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR091093A1 (es) Tienopirimidinas
AR071055A1 (es) Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas
AR090847A1 (es) Compuestos moduladores del receptor huerfano retinoideo (ror)
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
PE20191817A1 (es) Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
AR090879A1 (es) Acidos indanoiloxidihidrobenzofuranilaceticos
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR094550A1 (es) Inhibidores de btk
AR090955A1 (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del vih
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
BR112017026224A2 (pt) moduladores de ror gama (rory)

Legal Events

Date Code Title Description
FB Suspension of granting procedure